EML4-ALK fusion gene, first described five years ago in patients with lung adenocarcinoma, undoubtedly has oncogenic potential and represents a promising candidate for targeted therapy.     ///    "[EML4-ALK fusion gene in patients with lung carcinoma: biology, diagnostics and targeted therapy].. "    ///    "Therefore, novel, highly specific inhibitors able to overcome resistance of mutated EML4-ALK are needed. "    ///    EML4-ALK fusion occurs due to paracentric inversion in the short arm of chromosome 2 and is detected in 3-5% of patients with non-small cell lung cancer. 